文献速递白血病

接受低甲基化药物联合维奈克拉治疗的急性髓系白血病患者的预后风险特征

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
PubMed 文献 · Blood Adv · 2024-01-01

本研究在159例接受低甲基化药物(HMA)联合维奈克拉(Ven)治疗的急性髓系白血病(AML)患者中,回顾性验证了一种新提出的分子预后风险特征(mPRS)。mPRS将患者分为较高、中间和较低获益组,三组的总缓解率分别为86%、54%和59%,中位总生存期分别为30、12和5个月(P<.001),mPRS对总生存期和无事件生存期的区分能力优于ELN 2022分类。

要点

  • mPRS将患者分为较高、中间(N/KRAS或FLT3-内部串联重复突变)和较低(TP53突变)获益组。
  • 较高、中间、较低获益组的中位总生存期分别为30、12和5个月(P<.001)。
  • mPRS对总生存期和无事件生存期的C指数高于ELN 2022分类。

核心结论

  • mPRS分类能够准确区分接受HMA联合Ven治疗的AML患者群体。
  • 在这些患者中,N/KRAS和TP53突变似乎对结局产生负面影响,因此需要新的治疗方法。

研究设计与样本

  • 回顾性分析159例接受HMA联合Ven治疗的AML患者,验证新提出的分子预后风险特征(mPRS)。

主要发现

  • mPRS将74例(47%)、31例(19%)和54例(34%)患者分别归入较高、中间和较低获益组。
  • 总缓解率为71%,较高、中间和较低获益组分别为86%、54%和59%。
  • 较高、中间和较低获益组的中位总生存期分别为30、12和5个月,中位无事件生存期分别为19、8和4个月(P<.001)。
  • 按mPRS分类分层时,总生存期和无事件生存期的C指数高于ELN 2022分类。
  • 较高、中间和较低获益组的2年累积复发率分别为35%、70%和60%(P=.005)。

关键数值与推荐

  • mPRS分为较高获益组、中间获益组(N/KRAS或FLT3-内部串联重复突变)和较低获益组(TP53突变)。
  • 较高、中间、较低获益组的总缓解率分别为86%、54%和59%,总缓解率为71%。
  • 较高、中间、较低获益组的中位总生存期分别为30、12和5个月,中位无事件生存期分别为19、8和4个月(P<.001)。
  • 较高、中间、较低获益组的2年累积复发率分别为35%、70%和60%(P=.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, the European LeukemiaNet (ELN) risk classifications have been validated for patients treated with intensive therapy. In this study, we validate a recently proposed new molecular prognostic risk signature (mPRS) for patients with AML treated with HMAs and Ven. This classification allocated patients to favorable, intermediate (N/KRAS or FLT3-internal tandem duplication mutations), and lower (TP53 mutations) benefit groups. We retrospectively analyzed 159 patients treated with HMA and Ven. The mPRS classification allocated 74 (47%), 31 (19%), and 54 (34%) patients to the higher, intermediate, and lower-benefit groups, respectively. The overall response rate was 71% (86%, 54%, and 59% in the higher, intermediate, and lower-benefit groups, respectively). The median overall survival (OS) and event-free survival (EFS) times were 30 and 19 months, respectively, in the higher-benefit group; 12 and 8 months in the intermediate-benefit group; and 5 and 4 months in the lower-benefit group (P < .001). The C-index for OS and EFS was higher when stratifying patients according to mPRS classification than with the ELN 2022 classification. The 2-year cumulative incidence of relapse was 35%, 70%, and 60% in the higher, intermediate, and lower-benefit groups, respectively (P = .005). The mPRS classification accurately segregated groups of patients with AML treated with HMA plus Ven. In these patients, N/KRAS and TP53 mutations appear to negatively affect outcomes; therefore, new treatment approaches are warranted.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bataller A, Bazinet A, DiNardo CD, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024. PMID: 38113472. doi:10.1182/bloodadvances.2023011757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。